The FDA and state regulatory agencies should investigate unregulated direct access infusion businesses, according to a statement issued on Jan. 18 by the National Home Infusion Association (NHIA), ASHP, the American Society for Parenteral and Enteral Nutrition (ASPEN), and several allied organizations.
The groups asked the regulators to assess the impact of direct access infusion businesses on critical drug shortages and for states to regulate such businesses in a manner comparable